Market Preview, June 5, 2026: SEBI Warning for ICICI Bank, Aurobindo Pharma's USFDA Nod, Wipro Buyback Record Date, CG Power's EHV Plant and Tata Motors' 2030 Target to Keep Indian Investors Busy on Friday

Mumbai, June 5: Sebi has issued a warning to ICICI Bank while pharma company Aurobindo Pharma received USFDA clearance to launch its drug in the US market while Friday marks the record date for Wipro share buyback. Investors will also be tracking Tata Motors Passenger Vehicle shares as company has set ambitious target to capture 20% market by 2030. Here’s what you should track.

ICICI Bank

ICICI Bank (NSE: Rs 1,253) finds itself under regulatory scrutiny after the Securities and Exchange Board of India (SEBI) issued a warning letter to the private sector lender in its capacity as a custodian. The regulator acted after ICICI Bank permitted a foreign portfolio investor (FPI) to repatriate funds before the completion of the mandatory lock-in period prescribed under the Voluntary Retention Route (VRR) a dedicated channel designed to encourage longer-term FPI participation in Indian debt markets. The VRR framework requires investors to retain a minimum proportion of their investments in India for a defined period, and early repatriation without regulatory clearance constitutes a breach of those conditions. While the bank has not disclosed further details about the FPI involved or the quantum of funds repatriated, the warning letter from SEBI signals that the regulator views custodial compliance with VRR norms as a serious obligation. ICICI Bank, India’s second-largest private lender by assets, is one of the most prominent custodians in the country, and the development is likely to draw attention to the broader compliance culture around FPI custody services in Indian financial institutions.

Aurobindo Pharma

Hyderabad-based pharma major Aurobindo Pharma (NSE: Rs1,465.50) has secured a significant regulatory milestone in the United States, receiving final approval from the US Food and Drug Administration (USFDA) to manufacture and market Tofacitinib Tablets in 5 mg and 10 mg strengths. The approved product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD) Xeljanz Tablets, manufactured by PF Prism CV, which is a widely prescribed branded treatment for adults suffering from moderately to severely active rheumatoid arthritis a chronic autoimmune condition affecting millions of patients globally. The generic version will be manufactured at APL Healthcare Unit IV, a wholly owned subsidiary of Aurobindo Pharma, and the company has confirmed that commercial launch will be immediate, positioning it to capture a share of the US rheumatoid arthritis generics market without delay. Tofacitinib belongs to the Janus kinase (JAK) inhibitor class of drugs and has also been approved for other inflammatory conditions including psoriatic arthritis and ulcerative colitis in the US, broadening the eventual commercial opportunity for Aurobindo beyond rheumatoid arthritis alone. The USFDA nod adds to Aurobindo’s growing generics portfolio in the American market, where the company remains one of the most active Indian pharma players by volume of approvals.

CG Power and Industrial Solutions

CG Power and Industrial Solutions (NSE: Rs 941) has commissioned a new extra-high-voltage (EHV) switchgear manufacturing facility in Nashik, Maharashtra, marking a meaningful expansion of its domestic production infrastructure in the power equipment segment. The new facility is in addition to the company’s existing S3 Unit-I manufacturing plant at Ambad, Nashik, which already produces EHV circuit breakers across an extensive voltage range from 33kV all the way up to 800kV covering the full spectrum of transmission and sub-transmission requirements in India and export markets. The commissioning is strategically timed, given India’s accelerating investments in power transmission infrastructure as the government pursues ambitious renewable energy targets that require substantial grid expansion and upgradation. EHV switchgear is a critical component in high-voltage substations, and the ability to manufacture it domestically aligns with the broader push under India’s ‘Make in India’ framework to reduce dependence on imported power equipment. CG Power, which is now part of the Murugappa Group following its resolution and turnaround, has steadily rebuilt its manufacturing capabilities and order book, and the Nashik expansion strengthens its positioning in a domestic market that analysts expect will see sustained capital expenditure from central and state utilities over the next several years.

Wipro

Shares of Wipro (NSE: Rs204) will be closely watched on Friday, June 5, as the IT services major’s ₹15,000 crore share buyback reaches its record date a key milestone that determines which shareholders are eligible to tender their shares under the programme. The buyback represents the company’s largest such repurchase in nearly three years, underscoring management’s confidence in Wipro’s financial position and its intent to return surplus capital to shareholders at a time when IT sector deal momentum has been gradually recovering. Buyback record dates typically generate heightened short-term trading activity as arbitrageurs, institutional holders and retail investors assess their tendering decisions based on the buyback price vis-à-vis prevailing market prices. Wipro’s stock performance in the days leading up to and following the record date will be a key indicator of market sentiment around the buyback’s attractiveness. The development comes as Wipro navigates a competitive IT landscape shaped by enterprise spending caution and an accelerating shift towards AI-driven services, and management will be watching whether the buyback serves as an effective signal of long-term value to investors.

Tata Motors

Tata Motors (NSE: Rs 373.50) has set an ambitious market share target for itself in India’s passenger vehicle segment, with Chairman N. Chandrasekaran stating that the company should aim to capture more than 20% of the domestic passenger vehicle market by 2030 contingent on India’s overall passenger vehicle market expanding to 6 million units annually by that year. The target is a significant step up from Tata Motors’ current market positioning and reflects the company’s confidence in the sustained momentum of its passenger vehicle business, which has undergone a dramatic revival over the past few years driven largely by its successful electric vehicle lineup and refreshed internal combustion engine portfolio under the Tata and Nexon franchises. Achieving a 20%-plus share in a 6 million-unit market would translate to over 1.2 million vehicle sales per year from its domestic PV business alone, compared to volumes that are currently well below that threshold, implying a substantial ramp in production capacity, distribution reach, and product launches over the next four years. Chandrasekaran’s remarks signal that the Tata Group views its automotive arm as a long-term strategic pillar, particularly as electrification reshapes competitive dynamics and Tata Motors benefits from being an early mover in India’s EV transition. Investors will be watching for further details on the roadmap, capital allocation plans, and new model pipeline that would support such an ambitious growth trajectory in what remains a fiercely contested segment.

Source:

• https://www.bseindia.com/corporates/ann